Status:
RECRUITING
Y-90 Treatment Response Using Transarterial Radioembolization
Lead Sponsor:
Thomas Jefferson University
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
HCC
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This prospective clinical study will examine the ability of contrast-enhanced ultrasound (CEUS) to assess the treatment response of hepatocellular carcinoma (HCC) to transarterial radioembolization (T...
Detailed Description
Following baseline ultrasound imaging, CEUS will be performed using dual B-mode and CEUS mode. For the first injection using Lumason the approximate tumor mid-line will be imaged during breath hold un...
Eligibility Criteria
Inclusion
- Scheduled for TARE therapy of a treatment naïve HCC visible on ultrasound.
- Be at least 18 years of age.
- Be medically stable.
- If a female of child-bearing age, must have a negative pregnancy test.
- Have signed Informed Consent to participate in the study.
Exclusion
- Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable.
- Patients with known sensitivities to the components of Lumason.
- Patients with known sensitivities to the components of Sonazoid.
Key Trial Info
Start Date :
September 11 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2027
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT07145801
Start Date
September 11 2025
End Date
June 30 2027
Last Update
October 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107